Impact of the 2021 ESC Prevention Guideline's stepwise approach for cardiovascular risk factor treatment in patients with established ASCVD.
Joris HoltropDeepak L BhattKausik K RayFrançois MachYvo M SmuldersDavid CarballoPhilippe Gabriel StegFrank L J VisserenJannick A N DorresteijnPublished in: European journal of preventive cardiology (2024)
With current treatment residual CV risk in patients with ASCVD remains high across all European risk regions. The intensified Step 2 treatment options result in marked further reduction of residual CV risk in patients with established ASCVD.